Referencia número: HY-B1619

Cromolyn

(Synonyms: Cromoglycate; Cromoglicic acid; FPL-670 free acid)

11 Cited Publications

Revisión del cliente

Based on 11 publication(s) in Google Scholar

Cromolyn (Cromoglycate) is an orally active GSK-3β inhibitor with an IC₅₀ of 2.0 μM. Cromolyn is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn can be used in the research of bronchial asthma. In addition, Cromolyn has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.97%
No. CAS: 16110-51-3
Fòrmula: C₂₃H₁₆O₁₁
Peso molecular:468.37

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cromolyn Chemical Structure

No. CAS: 16110-51-3

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (11)
Solvente y solubilidad
- In Vitro
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Ver todos los productos específicos de isoformas GSK-3 :

Ver todos los productos específicos de isoformas NF-κB :

Cellular Effect

Cell Line	Type	Value	Description	References
Sf21	IC₅₀	>1000 μM Compound: Cromolyn	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	>1000 μM Compound: Cromolyn	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

In Vitro

Cromolyn (0-100 μM; 3-10 min) can inhibit IgE- and antigen-induced degranulation and PGD₂ synthesis in rat peritoneal mast cells^[1].
Cromolyn (0-100 μM; 0-72 h) can block S100P-promoted cell proliferation, invasion, and increased NF-κB activity in Panc-1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cromolyn (10 mg/kg; intravenous injection; single dose) can significantly inhibit mast cell activation in IgE-dependent PCA by reducing Evans blue extravasation and completely inhibit antigen-induced plasma histamine increase in PSA in rats^[1].
Cromolyn (5 mg/kg; intraperitoneal injection; 5 weeks) has anti-tumor activity in a mouse model of pancreatic cancer^[2].
Cromolyn (6.3 mg/kg; intraperitoneal injection; 5 times a week; from postnatal day 60 until euthanasia) has an ameliorative effect in a model of amyotrophic lateral sclerosis^[3].
Cromolyn (1-3.15 mg/kg; intraperitoneal injection; 3 times a week; 12 weeks) has a neuroprotective effect in a mouse model of Alzheimer's disease^[4].
Cromolyn (1.43-5.72 mg/kg; intraperitoneal injection; 1 month) has a hypoglycemic effect in mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male CB17 scid mice aged 4 weeks old treated BxPC-3 and MPanc-96 cells^[2]
Dosage:

5 mg/kg
Administration:

Intraperitoneal injection; 5 weeks
Result:

Significantly reduced tumor burden.
Reduced lung metastasis in the BxPC-3 model and both liver and lung metastases in the MPanc-96 model.
Had no effect on body weight.

Animal Model:

SOD1^G93A mice^[3]
Dosage:

6.3 mg/kg
Administration:

Intraperitoneal injection; 5 times a week; from postnatal day 60 until euthanasia
Result:

Delays disease onset.
Improved motor deficits in the PaGE task.
Increased survival of lumbar spinal cord motor neurons, decreased denervation at the neuromuscular junction.
Reduced pro-inflammatory cytokine and chemokine levels in the spinal cord and plasma.
Decreased mast cell degranulation in the tibialis anterior muscle.

Animal Model:

APP^Swedish expressing Tg2576 mice^[4]
Dosage:

1 and 3.15 mg/kg
Administration:

Intraperitoneal injection; 3 times a week; 12 weeks
Result:

Reduced the levels of Aβ40 and Aβ42 in brain TBS-insoluble fractions.
Increased the level of Aβ38.
Promoted the phagocytosis of β-amyloid by microglia.

Animal Model:

Normal Balb/c mice, chronic type II diabetic Balb/c mice, and chronic obese Balb/c mice^[5]
Dosage:

1.43, 2.86 and 5.72 mg/kg
Administration:

Intraperitoneal injection; 1 month
Result:

Dose-dependently reducted blood glucose, body weight, and resistin levels.
Increased liver glycogen, insulin, C-peptide, and adiponectin levels in mice.

Chemical Information

No. CAS 16110-51-3
Appearance Solid
Peso molecular 468.37
Fòrmula C₂₃H₁₆O₁₁
Color Off-white to light yellow
SMILES

OC(COC1=C2C(C=C(C(O)=O)OC2=CC=C1)=O)COC3=C4C(C=C(C(O)=O)OC4=CC=C3)=O
Synonyms

Cromoglycate; Cromoglicic acid; FPL-670 free acid
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (11)

All In Vivo Efficacy StudyCell Proliferation/Viability AssayIHC

Sort by:

Journal Impact Factor

Cancer Cell

Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. [Abstract]

2025 Mar 10;43(3):446-463.e7. PMID: 39919737

Cromolyn purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Mar 10;43(3):446-463.e7. [Abstract]

Cromolyn disodium (DSCG: 10 mg/kg). Experimental workflow and tumor growth of the murine 4T1 breast tumor model. Data on day 15 were presented.

Cromolyn purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Mar 10;43(3):446-463.e7. [Abstract]

Cromolyn disodium (DSCG: 10 mg/kg). GSVA scores of immune cell subsets after different treatments in the murine 4T1 breast tumor model.
Nat Commun

S100P is a ferroptosis suppressor to facilitate hepatocellular carcinoma development by rewiring lipid metabolism. [Abstract]

2025 Jan 8;16(1):509. PMID: 39779666

Cromolyn purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 8;16(1):509. [Abstract]

Cell viability of HT1080 S100P OE cells pretreated with indicated concentrations of Cromolyn disodium for 12 h and then treated with RSL3 (200 nM) for 6 h.
Pharmacol Res

Sinomenine-induced histamine release-like anaphylactoid reactions are blocked by tranilast via inhibiting NF-κB signaling. [Abstract]

2017 Nov;125(Pt B):150-160. PMID: 28867637

Cromolyn purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2017 Nov;125(Pt B):150-160. [Abstract]

The IL-33 production in different treatment groups is determined in rat skin by immunohistochemistry assay.
J Med Chem

Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. [Abstract]

2021 Oct 14;64(19):14344-14357. PMID: 34547896
J Invest Dermatol

MRGPRX2-Mediated Mast Cell Activation Promotes Malignant Progression of Cutaneous Squamous Cell Carcinoma through IL-17A Release. [Abstract]

2025 Nov 4:S0022-202X(25)03517-1. PMID: 41197765
Int J Mol Sci

Bile Canalicular Bitter Taste Receptors Inhibit β-Adrenergic Receptor-Induced Lipolysis in Steatotic Hepatocytes. [Abstract]

2026 Apr 2;27(7):3226. PMID: 41977407
Int Immunopharmacol

Edaravone attenuates cerebral inflammation by inhibiting mast cells degranulation via ROS/STIM1 signaling pathway in HIE model. [Abstract]

2025 May 19:159:114880. PMID: 40394799
Int J Mol Sci

Pro-Tumorigenic Effect of Continuous Cromolyn Treatment in Bladder Cancer. [Abstract]

2025 Feb 14;26(4):1619. PMID: 40004083
J Inflamm Res

Astragalus membranaceus and Salvia miltiorrhiza Inhibit Tryptase/PAR2-Mediated Mast Cells - Peritoneal Mesothelial Cells Crosstalk to Ameliorate Peritoneal Fibrosis. [Abstract]

2026 May 11:19:577472. PMID: 42147796
Mol Biol Rep

Disodium cromoglycate restricts human tau hyperphosphorylation and manifestation of associated phenotypes by inhibiting GSK3β activity in Drosophila disease models. [Abstract]

2026 Apr 7;53(1):589. PMID: 41945164
Res Sq

2025 Apr 08.

Solvente y solubilidad

In Vitro:

DMSO : 175 mg/mL (373.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1351 mL

10.6753 mL

21.3506 mL

5 mM

0.4270 mL

2.1351 mL

4.2701 mL

10 mM

0.2135 mL

1.0675 mL

2.1351 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (278 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Oka T, et al. Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. Lab Invest. 2012 Oct;92(10):1472-82. [Content Brief]

[2]. Arumugam T, et al. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18. [Content Brief]

[3]. Granucci EJ, et al. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Sci Rep. 2019 Nov 27;9(1):17728. [Content Brief]

[4]. Zhang C, et al. Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis. Sci Rep. 2018 Jan 18;8(1):1144. [Content Brief]

[5]. Motawi TM, et al. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J Biochem Mol Toxicol. 2013 Sep;27(9):425-36. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1351 mL	10.6753 mL	21.3506 mL	53.3766 mL
	5 mM	0.4270 mL	2.1351 mL	4.2701 mL	10.6753 mL
	10 mM	0.2135 mL	1.0675 mL	2.1351 mL	5.3377 mL
	15 mM	0.1423 mL	0.7117 mL	1.4234 mL	3.5584 mL
	20 mM	0.1068 mL	0.5338 mL	1.0675 mL	2.6688 mL
	25 mM	0.0854 mL	0.4270 mL	0.8540 mL	2.1351 mL
	30 mM	0.0712 mL	0.3558 mL	0.7117 mL	1.7792 mL
	40 mM	0.0534 mL	0.2669 mL	0.5338 mL	1.3344 mL
	50 mM	0.0427 mL	0.2135 mL	0.4270 mL	1.0675 mL
	60 mM	0.0356 mL	0.1779 mL	0.3558 mL	0.8896 mL
	80 mM	0.0267 mL	0.1334 mL	0.2669 mL	0.6672 mL
	100 mM	0.0214 mL	0.1068 mL	0.2135 mL	0.5338 mL

Keywords

Cromolyn

11 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Cromolyn

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

FDA Kinase Inhibitor Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Cromolyn

Ver todos los productos específicos de isoformas GSK-3

Ver todos los productos específicos de isoformas NF-κB

Actividad biológica

Chemical Information

Publications (11)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Cromolyn Related Classifications

HY-B1619 Related Classifications